| Cost-effectiveness of reperfusion strategies. | |
| | |
MedLine Citation:
|
PMID: 10426873 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Reperfusion of acute myocardial infarction has become the standard of management during the first few hours. Cost per year of life saved is one measure of the effectiveness of reperfusion strategies. Estimates of the cost per year of life saved have been approximately $17,000 for streptokinase and percutaneous transluminal coronary angioplasty and approximately $33,000 for tissue plasminogen activator. Assuming that percutaneous transluminal coronary angioplasty is more effective than thrombolysis, we calculated the cost-effectiveness of this strategy in different hospital settings. The estimated costs in hospitals with existing cardiac catheterization laboratories were $11,000 per year of life saved for primary angioplasty and $14,000 for thrombolysis compared with no intervention. In hospitals without catheterization facilities, it would be cost-ineffective to build such laboratories only to treat acute infarction with angioplasty. Preliminary results suggest that stenting may also be cost-effective in association with angioplasty. |
| | |
Authors:
|
W W Parmley |
Related Documents
:
|
15227193 - Distal coronary hemoperfusion and prolonged balloon inflation for acute occlusion: occu... 10080463 - Long-term outcome after primary angioplasty: report from the primary angioplasty in myo... 11096543 - Sarcoidosis and the heart. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Review |
Journal Detail:
|
Title: American heart journal Volume: 138 ISSN: 0002-8703 ISO Abbreviation: Am. Heart J. Publication Date: 1999 Aug |
Date Detail:
|
Created Date: 1999-08-30 Completed Date: 1999-08-30 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: S142-52 Citation Subset: AIM; IM |
Affiliation:
|
University of California, 505 Parnassus Avenue, San Francisco, CA 94143-0124, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary
/
economics Cost-Benefit Analysis Fibrinolytic Agents / economics Heart Catheterization / economics Hospital Costs Hospital Departments / economics Humans Laboratories / economics Myocardial Infarction / therapy Myocardial Reperfusion / economics*, methods Stents / economics Streptokinase / economics Tissue Plasminogen Activator / economics Value of Life |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gene therapy for myocardial angiogenesis.
Next Document: Current role of stenting in acute myocardial infarction.